Ancestor Stem Cell

Ancestor Stem Cell, founded in 2022 and led by Dr. Zhang Xiaoping, is a high-tech innovative enterprise focusing on stem cell and regenerative medicine technology. Relying on a top research team led by experts from the Chinese Academy of Sciences and clinical authorities, the company focuses on the development of stem cell drugs, the transformation of engineered exosome technology, and clinical solutions, building an integrated innovation platform of "industry-academia-research-medicine."The company owns a full-chain technology system, covering stem cell drugs, targeted engineered exosomes, and a GMP-level production system that meets NMPA/FDA standards, with significant clinical results. Ancestor Stem Cell-101 is the first stem cell drug for male treatment in China to obtain dual registration from the National Medical Products Administration (NMPA) and the National Health Commission.Currently, the company has deep cooperation with medical institutions such as Shanghai Ninth People's Hospital, Renji Hospital, and the Obstetrics and Gynecology Hospital affiliated with Fudan University. It is planning a base in the Yangtze River Delta region, committed to promoting the clinical transformation of regenerative medicine in the fields of anti-aging, sexual health, and medical aesthetics. With the mission of "decoding the language of cells, reshaping the vitality of life," it aims to build a world-leading cell therapy ecosystem and contribute to the future of life and health.